Abstract:Background: IBS and IBD are chronic gastrointestinal (GI) conditions associated with abdominal pain and abnormal bowel habits.Although IBS and IBD share common symptoms, their pathogenesis differs.Whereas IBD symptoms often arise from inflammatory or structural abnormalities, these objective markers are not consistently identified in IBS.Because symptom pathogenesis differs between disorders, we aimed to test whether symptom severity also varies between IBS and IBD.Methods: We compared GI symptoms using items developed for the NIH Patient Reported Outcome Measurement Information System (PROMIS®) that assessed frequency, severity, interference, and bother to 3 groups: (1) IBS patients from clinic and community populations, (2) IBD clinic patients, and (3) a U.S. general population (GP) sample selected by a commercial research firm (Cint) to approximate characteristics in the 2010 census.We measured 8 GI symptom domains: gastroesophageal reflux (GERD), disrupted swallowing, nausea/vomiting (N/V), belly pain, diarrhea, constipation, gas/bloating, and fecal incontinence/soling (FI).We measured overall symptom severity by averaging responses to items and transforming linearly to a 0-100 possible range (higher=worse).We compared group differences using analysis of covariance controlling for demographics and GI symptom-specific anxiety (Visceral Sensitivity Index [VSI]).To adjust for multiple comparisons for different symptoms, a p ,0.01 was used.Results: Respondents included 231 with IBS (mean age=44.8yrs; 68%F; 56.3% Caucasian), 190 with IBD (mean age=41.3yrs; 46%F; 58.4% Caucasian) and 1117 from the GP (mean age 45.7; 57%F; 72.7% Caucasian).Mean age, race/ethnicity, and education significantly differed between groups (all p ,0.01).The Table shows differences in GI symptom severity scores between groups.The GP had greater severity of GERD, disrupted swallowing and N/V compared to the patient groups.GERD severity differed among all groups with greatest severity in GP, followed by IBS, and then IBD.GP reported more disrupted swallowing than IBS and greater N/V than IBD.IBS patients reported greater severity of belly pain vs. GP and greater severity of constipation and gas/ bloating vs. GP and IBD.IBD patients had more severe diarrhea than the GP but not IBS.Conclusions: While IBS and IBD are conditions associated with greater lower GI symptom severity compared to the GP, they report less severe upper GI symptoms.Between disease states, IBS patients report numerically worse symptom severity vs. IBD for 7 of 8 GI symptom domains -only diarrhea appeared more severe in IBD.Although IBD is marked by objective inflammatory and anatomic biomarkers, this does not necessarily yield worse symptom severity than IBS -a condition without reliable biomarkers; the converse is true in this study.* P values after controlling for demographics and VSI.Values shown in bold are statistically significant.

How fragile the positive results of Chinese herbal medicine randomized controlled trials on irritable bowel syndrome are?

The Diagnosis Performance of the TCM Syndromes of Irritable Bowel Syndrome by Gastroenterologists Based on Modified Simple Criteria Compared to TCM Practitioners: A Prospective, Multicenter Preliminary Study

Tu2066 Prevalence of Irritable Bowel Syndrome in China: Joint Effects of Psychiatric Morbidity with Life Event Stress and Lactose Intake

Psychological Factors May Affect the Quality of Life in Irritable Bowel Syndrome Patients More Than the Gut Itself? A Multicenter Cross‐sectional Study

Using PRECIS-2 in Chinese herbal medicine randomized controlled trials for irritable bowel syndrome: A methodological exploration based on literature

Fragility index analysis for randomized controlled trials of approved biologicals and small molecule drugs in inflammatory bowel diseases

Pharmacological treatments of Chinese herbal medicine for irritable bowel syndrome in adults: A network meta-analysis of randomized controlled trials

A Meta Analysis for Randomized Controlled Trails of Constipation Patients Treated with Traditional Chinese Medicine

The fragility index in randomized clinical trials supporting clinical practice guidelines for acute coronary syndrome: measuring robustness from a different perspective

Intestinal Microecology and Quality of Life in Irritable Bowel Syndrome Patients

[Some Ideas Regarding Establishment of Chinese Medicine Clinical Assessment Indices System for Studying Irritable Bowel Syndrome].

Fragility of overactive bladder medication clinical trials: A systematic review

Irritable Bowel Syndrome Consulters in Zhejiang Province: the Symptoms Pattern, Predominant Bowel Habit Subgroups and Quality of Life.

Trial characteristics and treatment effect estimates in randomized controlled trials of Chinese herbal medicine: A meta-epidemiological study

Fragility in cardiovascular randomized controlled trials with primary continuous outcomes (2018–2022) from multi-perspectives assessment: a cross-sectional survey

Treatment of Diarrhea-Predominant Irritable Bowel Syndrome with Traditional Chinese Herbal Medicine: A Randomized Placebo-Controlled Trial

Study on clinical significance of different subgroups of irritable bowel syndrome patients in Zhejiang province

SF-36 quality of life in effectiveness ssessment for irritable bowel syndrome

Inflammatory bowel disease: an overview of Chinese herbal medicine formula-based treatment

Assessing the fragility index of randomized controlled trials supporting perioperative care guidelines: A methodological survey protocol

Questionnaire Analysis of Irritable Bowel Syndrome Overlapping with Functional Dyspepsia